Carvykti joins Abecma in adcom limbo
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
OncoC4 takes its Siglec-10 bet into the clinic
The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.
ASCO-GI – Leap falters again
Randomised data will be needed to answer lingering questions about DKN-01.
T-cell engagers enter new pivotal studies
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
ASCO-GI – confirmation for Bristol’s combo, but is there more?
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
ASCO-GI – some shine comes off Astra’s Emerald
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
ASCO-GI – another surprising TIGIT success?
Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.
Car-T comes full circle
Bristol renews its focus on chronic lymphocytic leukaemia, but rivals haven’t fared so well here.
Merck KGaA’s oncology catalyst approaches
Three years after licensing in the IAP inhibitor xevinapant Merck KGaA will find out if the deal was worth it.
New phase 1 projects enter hot fields
Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.
